Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis

Background: Considerable evidence implicates myeloid-derived suppressor cells (MDSCs) promote tumor progression and drug resistance. Sorafenib is the standard first-line therapy for advanced hepatocellular carcinoma (HCC). Clinical evidence indicates that sorafenib resistance is associated with incr...

Description complète

Détails bibliographiques

Auteurs principaux:	Xue Deng, Xueyan Li, Xuan Guo, Yantong Lu, Yingjie Xie, Xuhui Huang, Juze Lin, Wei Tan, Changjun Wang
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2022-06-01
Collection:	Neoplasia: An International Journal for Oncology Research
Sujets:	Myeloid cells Hepatocellular carcinoma Sorafenib Fibroblast cells Combination therapy
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S1476558622000173
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!